CONNECT WITH US
HealthTech

HealthTech

Analysts press Biogen on lupus drug litifilimab ahead of pivotal readouts

Endpoints News logo

Published on

Add as a preferred source on Google
Analysts press Biogen on lupus drug litifilimab ahead of pivotal readouts

Scruti­ny of Bio­gen’s late-stage pipeline is in­ten­si­fy­ing ahead of sev­er­al Phase 3 read­outs that are piv­otal to CEO Chris Viehbach­er’s turn­around ef­forts.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfiz­er In­dia site clo­sure risks ex­ac­er­bat­ing can­cer drug short­ages October 28, 2026

Trea­sury's COINS rule draft would nar­row the path for Chi­na biotech deal­mak­ing, ex­perts say October 27, 2026

Lil­ly's ads can con­tin­ue af­ter No­vo chal­lenge, judge rules October 27, 2026

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape

Now 78% of sci­en­tists say AI will speed drug dis­cov­ery this year: Sig­nal Sur­vey



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.